There were 78 patients diagnosed with EGFR-mutated NSCLC and BM in Beijing Chest Hospital between August 2009 and May 2015.48 untreated patients who received both WBRT and EGFR-tyrosine kinase inhibitors (TKIs) therapy.Prognostic factors of intracranial progression-free survival (PFS) and overall survival (OS) were identified by Cox proportional hazards modeling. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.